晚期气动压缩装置对静脉淋巴水肿患者的健康与经济益处
基于2012至2016年Blue Health Intelligence的去标识私人保险理赔数据,对静脉淋巴水肿患者进行纵向匹配病例对照分析,比较Flexitouch晚期气动压缩装置与保守治疗、简单气动压缩装置及其他晚期气动压缩装置的医疗资源利用和成本。结果显示Flexitouch与较低的总成本、住院次数及蜂窝织炎发生率相关。
要点
- 与保守治疗相比,Flexitouch与每患者每年静脉淋巴水肿及后遗症相关总成本降低69%相关(3839美元 vs 12253美元;P=0.001)。
- 与简单气动压缩装置相比,Flexitouch与总成本降低85%相关(1153美元 vs 7449美元;P=0.008)。
- 与其他晚期气动压缩装置相比,Flexitouch与总成本降低53%相关(3973美元 vs 8436美元;P=0.032),且蜂窝织炎发生率较低(22.4% vs 44.9%的患者;P=0.02)。
核心结论
- 该分析表明,与替代压缩治疗相比,Flexitouch具有显著益处,有助于减轻静脉淋巴水肿的明显经济负担。
研究设计与样本
- 纵向匹配病例对照分析,使用Blue Health Intelligence 2012年至2016年完整年度的去标识私人保险理赔数据。
- 患者连续入组至少18个月,诊断为静脉淋巴水肿,并至少有一次保守治疗(单独或联合气动压缩)的理赔记录。
- 匹配后各组样本量:保守治疗86例(Flexitouch 87例),简单气动压缩装置34例(Flexitouch 23例),其他晚期气动压缩装置69例(Flexitouch 67例)。
主要发现
- 与保守治疗相比,Flexitouch与每患者每年静脉淋巴水肿及后遗症相关总成本(扣除任何气动压缩装置相关成本后)降低69%相关(3839美元 vs 12253美元;P=0.001)。
- 与保守治疗相比,Flexitouch与平均年住院次数减少59%相关(0.13 vs 0.32;P<0.001),对应住院成本降低82%、门诊医院成本降低55%、门诊物理治疗和职业治疗成本降低52%、其他门诊相关成本降低56%。
- 与简单气动压缩装置相比,Flexitouch与总成本降低85%相关(1153美元 vs 7449美元;P=0.008),由住院成本降低93%(297美元 vs 4215美元;P=0.002)、门诊医院成本降低84%(368美元 vs 2347美元;P=0.020)和其他门诊相关成本降低85%(353美元 vs 2313美元;P=0.023)驱动。
- 与其他晚期气动压缩装置相比,Flexitouch与总成本降低53%相关(3973美元 vs 8436美元;P=0.032),归因于较低的门诊成本和较低的蜂窝织炎发生率(22.4% vs 44.9%的患者;P=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Phlebolymphedema (chronic venous insufficiency-related lymphedema) is a common and costly condition. Nevertheless, there is a dearth of evidence comparing phlebolymphedema therapeutic interventions. This study sought to examine the medical resource utilization and phlebolymphedema-related cost associated with Flexitouch (FLX; Tactile Medical, Minneapolis, Minn) advanced pneumatic compression devices (APCDs) relative to conservative therapy (CONS) alone, simple pneumatic compression devices (SPCDs), and other APCDs in a representative U.S. population of phlebolymphedema patients. METHODS: This was a longitudinal matched case-control analysis of deidentified private insurance claims. The study used administrative claims data from Blue Health Intelligence for the complete years 2012 through 2016. Patients were continuously enrolled for at least 18 months, diagnosed with phlebolymphedema, and received at least one claim for CONS either alone or in addition to pneumatic compression (SPCDs or APCDs). The main outcomes included direct phlebolymphedema- and sequelae-related medical resource utilization and costs. RESULTS: After case matching, the study included 86 patients on CONS (87 on FLX), 34 on SPCDs (23 on FLX), and 69 on other APCDs (67 on FLX). Compared with CONS, FLX was associated with 69% lower per patient per year total phlebolymphedema- and sequelae-related costs net of any pneumatic compression device-related costs ($3839 vs $12,253; P = .001). This was driven by 59% fewer mean annual hospitalizations (0.13 vs 0.32; P < .001) corresponding to 82% lower inpatient costs and 55% lower outpatient hospital costs. FLX was also associated with 52% lower outpatient physical therapy and occupational therapy costs and 56% lower other outpatient-related costs. Compared with SPCDs, FLX was associated with 85% lower total costs ($1153 vs $7449; P = .008) driven by 93% lower inpatient costs ($297 vs $4215; P = .002), 84% lower outpatient hospital costs ($368 vs $2347; P = .020), and 85% lower other outpatient-related costs ($353 vs $2313; P = .023). Compared with APCDs, FLX was associated with 53% lower total costs ($3973 vs $8436; P = .032) because of lower outpatient costs and lower rates of cellulitis (22.4% vs 44.9% of patients; P = .02). CONCLUSIONS: This analysis indicates significant benefits attributable to FLX compared with alternative compression therapies that can help reduce the notable economic burden of phlebolymphedema.
引用
- Lerman M, Gaebler JA, Hoy S, et al. Health and economic benefits of advanced pneumatic compression devices in patients with phlebolymphedema. J Vasc Surg. 2018. PMID: 29914829. doi:10.1016/j.jvs.2018.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。